Skip to content

Study · Randomized controlled trial · 2018

4 results

Saliva oxytocin measures do not reflect peripheral plasma concentrations after intranasal oxytocin administration in men.

Quintana DS, Westlye LT, Smerud KT, Mahmoud RA, Andreassen OA, Djupesland PG

Hormones and behavior16 May 2018Cited by 41 (Europe PMC)

PMID29750971 (opens in a new tab)DOI10.1016/j.yhbeh.2018.05.004 (opens in a new tab)PepBankPUB-29750971
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In men, intranasal oxytocin at 8 IU and 24 IU raised saliva oxytocin concentrations compared with placebo.

    In plain wordsIn men, oxytocin nasal spray raised oxytocin levels in saliva compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseSaliva oxytocin concentration after intranasal oxytocin versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    8 IU, 24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    We found that intranasal oxytocin (8 IU and 24 IU) administration increased saliva oxytocin concentrations in comparison to saliva oxytocin concentration levels after intravenous and placebo administration.
    1 context sentence
    Summary · context
    In this study, saliva and plasma oxytocin was assessed after two doses of Exhalation Delivery System delivered intranasal oxytocin (8 IU and 24 IU), intravenous oxytocin (1 IU) and placebo in a double-dummy, within-subjects design with men.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In men, intranasal oxytocin at 8 IU and 24 IU raised saliva oxytocin concentrations compared with intravenous oxytocin.

    In plain wordsIn men, oxytocin nasal spray raised oxytocin levels in saliva more than oxytocin given into a vein.

    Peptide
    Oxytocin
    Outcome
    IncreaseSaliva oxytocin concentration after intranasal oxytocin versus intravenous oxytocin
    Study

    n: not reported in source

    Comparator
    Intravenous oxytocin 1 IU
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    8 IU, 24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    We found that intranasal oxytocin (8 IU and 24 IU) administration increased saliva oxytocin concentrations in comparison to saliva oxytocin concentration levels after intravenous and placebo administration.
    1 context sentence
    Summary · context
    In this study, saliva and plasma oxytocin was assessed after two doses of Exhalation Delivery System delivered intranasal oxytocin (8 IU and 24 IU), intravenous oxytocin (1 IU) and placebo in a double-dummy, within-subjects design with men.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In men, saliva oxytocin concentrations were not significantly associated with plasma oxytocin concentrations after intranasal oxytocin.

    In plain wordsIn men, oxytocin in saliva did not track oxytocin in blood after oxytocin nasal spray.

    Peptide
    Oxytocin
    Outcome
    No significant changeAssociation of saliva and plasma oxytocin after intranasal oxytocin
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    8 IU, 24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Additionally, we found that saliva oxytocin concentrations were not significantly associated with plasma oxytocin concentrations after either intranasal or intravenous oxytocin administration.
    1 context sentence
    Summary · context
    In this study, saliva and plasma oxytocin was assessed after two doses of Exhalation Delivery System delivered intranasal oxytocin (8 IU and 24 IU), intravenous oxytocin (1 IU) and placebo in a double-dummy, within-subjects design with men.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In men, saliva oxytocin concentrations were not significantly associated with plasma oxytocin concentrations after intravenous oxytocin.

    In plain wordsIn men, oxytocin in saliva did not track oxytocin in blood after oxytocin given into a vein.

    Peptide
    Oxytocin
    Outcome
    No significant changeAssociation of saliva and plasma oxytocin after intravenous oxytocin
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 IU · intravenousAs given in this study (human).

    Source sentences

    Summary
    Additionally, we found that saliva oxytocin concentrations were not significantly associated with plasma oxytocin concentrations after either intranasal or intravenous oxytocin administration.
    1 context sentence
    Summary · context
    In this study, saliva and plasma oxytocin was assessed after two doses of Exhalation Delivery System delivered intranasal oxytocin (8 IU and 24 IU), intravenous oxytocin (1 IU) and placebo in a double-dummy, within-subjects design with men.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.